Tarsus Pharmaceuticals, Inc. (TARS) stock
TARSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/304% above fair value
$78.20−0.48 (-0.61%)
Close on Nov 17, 2026Market cap $3.43BP/E –Yield 0.00%
Tarsus Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Tarsus Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $87.68M, up 48.6% year over year. For fiscal 2025 it was $64.32M, up 20.5% from the year before. The highest annual figure on record is $64.32M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $64.32M | +20.5% |
| FY2024 | Dec 31, 2024 | $53.39M | +6.1% |
| FY2023 | Dec 31, 2023 | $50.31M | +18.0% |
| FY2022 | Dec 31, 2022 | $42.62M | +2.2% |
| FY2021 | Dec 31, 2021 | $41.71M | +121.6% |
| FY2020 | Dec 31, 2020 | $18.83M | +495.4% |
| FY2019 | Dec 31, 2019 | $3.16M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $31.01M | +98.9% |
| Q1 FY2026 | Mar 31, 2026 | $22.35M | +55.1% |
| Q4 FY2025 | Dec 31, 2025 | $18.04M | +6.9% |
| Q3 FY2025 | Sep 30, 2025 | $16.28M | +34.3% |
| Q2 FY2025 | Jun 30, 2025 | $15.59M | +26.6% |
| Q1 FY2025 | Mar 31, 2025 | $14.41M | +19.4% |
| Q4 FY2024 | Dec 31, 2024 | $16.87M | +26.8% |
| Q3 FY2024 | Sep 30, 2024 | $12.13M | +0.2% |
| Q2 FY2024 | Jun 30, 2024 | $12.32M | -1.8% |
| Q1 FY2024 | Mar 31, 2024 | $12.07M | -2.3% |
| Q4 FY2023 | Dec 31, 2023 | $13.31M | +32.7% |
| Q3 FY2023 | Sep 30, 2023 | $12.11M | +10.9% |
| Q2 FY2023 | Jun 30, 2023 | $12.55M | +30.6% |
| Q1 FY2023 | Mar 31, 2023 | $12.36M | +2.3% |
| Q4 FY2022 | Dec 31, 2022 | $10.03M | +24.8% |
| Q3 FY2022 | Sep 30, 2022 | $10.91M | +6.9% |
| Q2 FY2022 | Jun 30, 2022 | $9.60M | +33.3% |
| Q1 FY2022 | Mar 31, 2022 | $12.08M | -25.7% |
| Q4 FY2021 | Dec 31, 2021 | $8.04M | +5.9% |
| Q3 FY2021 | Sep 30, 2021 | $10.21M | +27.8% |
| Q2 FY2021 | Jun 30, 2021 | $7.20M | +314.7% |
| Q1 FY2021 | Mar 31, 2021 | $16.26M | +975.5% |
| Q4 FY2020 | Dec 31, 2020 | $7.59M | +988.5% |
| Q3 FY2020 | Sep 30, 2020 | $7.99M | +1902.8% |
| Q2 FY2020 | Jun 30, 2020 | $1.74M | – |
| Q1 FY2020 | Mar 31, 2020 | $1.51M | – |
| Q4 FY2019 | Dec 31, 2019 | $697.00K | – |
| Q3 FY2019 | Sep 30, 2019 | $399.00K | – |
See a number that looks wrong?